Filing Flows › Comparisons › RMD vs DXCM
ResMed vs DexCom: RMD and DXCM compared
ResMed is the larger company: $1.4B of revenue in its latest quarter (Q1 FY27) against $1.3B for DexCom (Q3 2026). DexCom is growing faster (+11% against +6% a year earlier). ResMed is more profitable, with an operating margin of 32.0% against 24.3%.
Where the money goes: RMD and DXCM
ResMed (RMD) · Q1 FY27
ResMed, Q1 FY27: revenue $1.4B (+6% year over year), operating margin 32.0%, net earnings $418M, operating cash flow $422M. The chart follows the revenue to costs, profit and cash.
DexCom (DXCM) · Q3 2026
DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.
| ResMed (RMD) | DexCom (DXCM) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q3 2026 |
| Revenue | $1.4B | $1.3B |
| Revenue growth, Y/Y | +6% | +11% |
| Gross margin | 61.5% | 64.3% |
| Operating margin | 32.0% | 24.3% |
| Net earnings | $418M | $275M |
| Net margin | 29.6% | 20.5% |
| Operating cash flow | $422M | $326M |
| Free cash flow | $374M | $273M |
| Market value | $33.5B | $30.6B |
| P/E | 21.3× | 31.5× |
| Analysts’ mean target | $264.33 | $98.15 |
Where the revenue comes from
ResMed
- Total Sleep and Breathing Health: $1.3B (89%)
- Residential Care Software: $155M (11%)
Questions
Which is bigger, ResMed or DexCom?
ResMed is the larger company: $1.4B of revenue in its latest quarter (Q1 FY27) against $1.3B for DexCom (Q3 2026).
Is ResMed or DexCom growing faster?
DexCom is growing faster (+11% against +6% a year earlier).
Which is more profitable, ResMed or DexCom?
ResMed is more profitable, with an operating margin of 32.0% against 24.3%.
More: ResMed earnings · how ResMed makes money · DexCom earnings · how DexCom makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.